Exscientia welcomes Richard J. Law, as their new Chief Business Officer

GPCR News
Mar 1, 2022
1 min read

March 2022

"Congratulations to Richard J. Law, our newly named Chief Business Officer. Richard is the architect behind nearly all of Exscientia's partnerships and collaborations across pharma and #biotech⁠ and is an advocate for the role of #AI in drug discovery."

Recent Posts

See All

Emerging approaches for decoding neuropeptide transmission

November 2022 "Neuropeptides produce robust effects on behavior across species, and recent research has benefited from advances in...

Location bias contributes to functionally selective responses of biased CXCR3 agonists

November 2022 "Some G protein-coupled receptor (GPCR) ligands act as "biased agonists" that preferentially activate specific signaling...

Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...

November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis...